Bharat Biotech's Typbar TCV®, the first typhoid conjugate vaccine (TCV) to receive WHO prequalification in December 2017, was supplied to Pakistan in 2018 under a Gavi (The Vaccine Alliance) supported program for a large-scale introduction campaign.